The University of Osaka · Medicine
Professor Norikatsu Miyoshi's research lab focuses on cancer biology and molecular oncology, with a particular emphasis on the role of pluripotency factors, epigenetic regulation, and novel biomarkers in gastrointestinal cancers. The lab investigates how reprogramming factors and epigenetic modifications—such as DNA methylation dynamics and 5-methylcytosine erasure—contribute to cancer progression and treatment response. Key research directions include identifying prognostic markers like TRIB3, ANXA9, and SCRN1 in colorectal and esophageal cancers, and exploring the implications of these markers for patient survival and therapy. The lab also examines the impact of chemotherapy-induced myelotoxicity on clinical outcomes in advanced cancer patients.
Figures are computed from collected data and may differ slightly.
Although cancer is a disease with genetic and epigenetic origins, the possible effects of reprogramming by defined factors remain to be fully understood. We studied the effects of the induction or inhibition of cancer-related genes and immature status-related genes whose alterations have been reported in gastrointestinal cancer cells. Retroviral-mediated introduction of induced pluripotent stem (iPS) cell genes was necessary for inducing the expression of immature status-related proteins, includ
These data strongly suggest the usefulness of TRIB3 as a marker for predicting the prognosis of CRC patients, showing a basis for the development of effective treatments for CRC.
The genome-wide depletion of 5-methylcytosines (5meCs) caused by passive dilution through DNA synthesis without daughter strand methylation and active enzymatic processes resulting in replacement of 5meCs with unmethylated cytosines is a hallmark of primordial germ cells (PGCs). Although recent studies have shown that in vitro differentiation of pluripotent stem cells (PSCs) to PGC-like cells (PGCLCs) mimics the in vivo differentiation of epiblast cells to PGCs, how DNA methylation status of PGC
In patients with T4 esophageal cancer who receive CRT followed by curatively resection, myelogenic chemotoxicity is a significant prognostic factor.
Annexin A9 (<i>ANXA9</i>) is involved with the interaction with membrane phospholipids in a Ca<sup>2+</sup>-dependent manner. A previous study has shown that <i>ANXA9</i> expression is associated with bone metastasis in breast cancer, whereas its significance in colorectal cancer (CRC) is unknown. The present study was comprised of 100 patients who underwent surgery for CRC. The correlation between gene expression and the clinical parameters of the patients was assessed. Patients with high <i>AN
The present data strongly suggest that SCRN1 expression is a prognostic factor in CRC patients.
The submucosal invasion depth predicts prognosis in early colorectal cancer. Although colorectal cancer with shallow submucosal invasion can be treated via endoscopic resection, colorectal cancer with deep submucosal invasion requires surgical colectomy. However, accurately diagnosing the depth of submucosal invasion via endoscopy is difficult. We developed a tool to diagnose the depth of submucosal invasion in early colorectal cancer using artificial intelligence. We reviewed data from 196 pati
Open papers in the app to read, cite, and organize with AI.
